Using Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) to improve access to obesity pharmacotherapy: A practical guide for clinicians caring for youth with obesity across United States Medicaid programs Authors: Jaime M Moore, Valerie M O'Hara, Cassie Totman, Brooke Sweeney, Sarah Hampl, Alaina P Vidmar Published: 2026 ABSTRACT AbstractBackgroundCoverage of obesity pharmacotherapy for youth varies substantially across state Medicaid programs. This variability limits access to evidence-based treatment for pediatric obesity. The Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit is a federally mandated Medicaid provision requiring coverage of medically necessary services for individuals under age 21, even when such services are not included in standard state Medicaid benefits. Despite its broad scope, EPSDT remains underutilized due to limited awareness and operational complexity.MethodsWe developed a clinician-facing, practice-oriented framework to operationalize EPSDT for pediatric obesity treatment. This approach integrates (1) review of federal EPSDT policy and statutory requirements, (2) synthesis of state-level variability in implementation, and (3) aggregation of real-world clinical workflows from centers that have successfully obtained EPSDT coverage for obesity pharmacotherapy. We outline step-by-step processes for identifying eligible patients, documenting medical necessity, submitting prior authorization requests, and managing appeals. Standardized tools, including sample letters of medical necessity, documentation templates, and clinic workflow algorithms, were created to support implementation across diverse clinical settings.ResultsKey components include: (1) reframing obesity as a chronic disease with documented comorbid risk to establish medical necessity; (2) aligning clinical documentation with EPSDT statutory language; (3) integrating multidisciplinary team roles to streamline submission and follow-up; and (4) implementing structured appeal pathways when initial requests are denied. Case-based examples and state-specific considerations highlight variability in payer response and demonstrate that EPSDT can effectively override standard Medicaid exclusions when appropriately applied.ConclusionsEPSDT represents a powerful but underutilized mechanism to expand equitable access to evidence-based obesity treatment for children and adolescents. A structured, clinician-driven approach can facilitate successful navigation of this benefit across diverse practice settings. Broader dissemination and adoption of standardized workflows may reduce disparities in access to obesity pharmacotherapy and support more consistent delivery of guideline-concordant care for pediatric obesity.Keywords: Early and periodic screening; Diagnostic, and treatment; Obesity medications; Pediatric obesity Introduction Pediatric obesity affects nearly 20% of youth in the United States and disproportionately impacts low-income populations insured by Medicaid [1,2]. Newer obesity medications like glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RA), dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GLP-1/GIP RA) and other Food and Drug Administration (FDA)-approved drugs like phentermine/topiramate, have demonstrated clinically meaningful reductions in body mass index (BMI) and improvements in cardiometabolic risk factors [3]. Effective treatment of childhood obesity is critical to reduce morbidity and mortality and has significant individual, public health, and economic benefits [[4], [5], [6], [7]]. However, coverage of evidence-based treatment including medications for youth with obesity without diabetes remains inconsistent across Medicaid programs [[4], [5], [6], [7]]. Many Medicaid formularies simply omit obesity medications or restrict them to narrow indications, leaving low-income families unable to afford treatments that are standard of care [8,9]. The Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit is a federal legal safety net that ensures that all medically necessary treatment for a child's health, including obesity, is covered [8,9]. Historical background and scope of EPSDT EPSDT was established in 1967 under Title XIX of the Social Security Act [[10], [11], [12], [13], [14]]. EPSDT was born as part of Medicaid's founding vision to provide comprehensive, preventive care to disadvantaged children [[10], [11], [12], [13], [14]]. It exists not as an optional add-on but as a core, federally mandated commitment: to cover services that Medicaid does not, to intervene early in life, to screen and diagnose conditions, and to treat any acute or chronic condition based on medical necessity, even when comparable adult coverage does not exist [[10], [11], [12], [13], [14]]. Its core purpose is to fill the void left by traditional (adult-centric) coverage [[15], [16], [17]]. In other words, EPSDT ensures that medical needs identified in childhood are addressed early and in full, rather than deferred or ignored due to coverage gaps [18]. The benefit is non-discretionary. It must be implemented in every state for Medicaid enrollees under 21 years of age [[10], [11], [12], [13], [14]]. However, each state decides how to interpret, fund, and operationalize EPSDT [[10], [11], [12], [13], [14]]. The same language in federal law gives rise to different interpretations of “medically necessary”, and funding, staffing, and timelines for review and appeals are also influenced by local legal opinions and resource constraints [[10], [11], [12], [13], [14]]. However, the Center for Medicare and Medicaid Services State Medicaid Manual is clear that “the amount, duration, or scope of EPSDT services to recipients may not be denied arbitrarily or reduced solely because of the diagnosis, type of illness, or condition” [19]. Childhood obesity treatment fulfills a fundamental objective of EPSDT, which is to intervene before a condition becomes more complex and treatment more costly. Because EPSDT overrides adult benefit limitations and formulary exclusions, evidence-based medications including those to treat obesity, can and should be furnished when prescribed by a qualified clinician [8,9]. Understanding this background highlights why a one-size-fits-all approach to EPSDT does not exist and why clinicians must often navigate state-specific rules and processes even though the underlying federal mandate is the same [[10], [11], [12], [13], [14]]. Core components of EPSDT By definition, EPSDT encompasses the following components [[10], [11], [12], [13], [14]]: Early: Initiation of interventions from birth onward. For example, some states use EPSDT to cover specialized evaluations for developmental delay and newborn metabolic screenings beyond standard testing, emphasizing the importance of preventive healthcare early in life. Periodic: Regular visits at established intervals throughout childhood and adolescence that augment and are in addition to the standard well child visit schedule (already covered by Medicaid) and provide more opportunities to detect emerging health issues. Screening: Comprehensive physical, mental, developmental, nutrition, vision, hearing, and dental screenings to identify potential health problems. Height and weight are specifically highlighted as key indices of nutritional status necessary to identify obesity. The goal is to detect conditions as early as possible. Diagnostic: Follow-up evaluation for any issue identified by a screening. If a screening suggests a possible condition (e.g., elevated BMI, signs of depression, developmental delay), EPSDT requires coverage of the evaluation services needed to achieve diagnostic clarity (such as laboratory tests, specialist evaluations, or imaging). Treatment: Any medically necessary treatment or service to “correct or ameliorate” a defect, illness, or condition identified. In the context of obesity, this treatment mandate means that all evidence-based obesity treatments (lifestyle, medications, surgery) must be covered for children if deemed medically necessary. EPSDT's treatment requirement is expansive and unequivocal with the aim to correct or at least improve a condition, not to merely maintain the status quo [19]. Why EPSDT matters for pediatric obesity care Obesity is one of the most prevalent chronic diseases of childhood in the US with profound physical, metabolic, and psychosocial consequences [20]. Left untreated, pediatric obesity significantly increases the risk for type 2 diabetes, cardiovascular disease, metabolic dysfunction associated steatotic liver disease, obstructive sleep apnea, orthopedic complications, and mental health disorders [20]. Early intervention is critical [21]. The 2023 American Academy of Pediatrics (AAP) Clinical Practice Guideline (and other professional society guidelines) explicitly recommend offering pharmacotherapy as an adjunct to lifestyle according to medication indications, risks, and benefits for youth ≥12 years old with obesity (BMI ≥95th percentile) and to consider for youth ages 8–11 years old in select severe cases [20,22]. However, lack of insurance coverage is a major barrier to implementing these recommendations. Because obesity has historically been stigmatized and not uniformly recognized as a disease by payers, treatments for pediatric obesity have been undervalued and often not covered [1,2]. Young people with obesity are too often denied the therapies that we routinely provide for other chronic diseases. For example, no one questions coverage for insulin and medical nutrition therapy by a dietitian in a child with type 1 diabetes, or a blood pressure lowering medication for hypertension, but a GLP-1 RA and coverage for intensive health and behavior lifestyle treatment for a child with severe obesity and/or prediabetes may be summarily denied if the payer classifies obesity as a lifestyle choice not a disease. This disparity is rooted in bias and outdated notions of obesity care [8,9]. EPSDT is a crucial federal tool to counteract these barriers. It provides a legal avenue to ensure that all medically necessary obesity treatments are accessible to Medicaid-enrolled youth [8,9]. Under the Medicaid Drug Rebate Program, states must cover all FDA-approved prescription drugs, but they can opt out of certain categories [[23], [24], [25]]. “Agents used for weight loss” is one such optional category [26], highlighting outdated, non-scientific descriptions of obesity as a personal failing or lifestyle choice and treatment as cosmetic. As a result, many Medicaid programs do not cover obesity medications for adults. However, for children and adolescents, EPSDT supersedes those exclusions, which should enable coverage of treatments like GLP-1 RAs (e.g., liraglutide [Saxenda®], semaglutide [Wegovy®]), phentermine/topiramate (Qsymia®, approved for ≥12 years), and any other medically necessary treatment. By contrast, GLP-1 medications approved for type 2 diabetes (such as injectable semaglutide as Ozempic®, oral semaglutide as Rybelsus®, liraglutide as Victoza®, and tirzepatide as Mounjaro®) must be covered by Medicaid for their indicated use (diabetes) due to mandatory coverage of diabetes medications [25]. As of January 2026, only 13 state Medicaid programs explicitly covered GLP-1 medications for obesity treatment in adults or adolescents through their standard policies, and nearly all of those impose strict prior authorization criteria, which is inconsistent with national scientific guidelines (e.g. BMI above certain thresholds, documented failure of lifestyle intervention, or specialist prescribing which directly contradict the current clinical practice guidelines from the American Academy of Pediatrics) [20,27]. The majority of states still exclude or do not mention obesity drugs in their adult Medicaid benefit, thereby denying them by default. The EPSDT benefit encompasses prescription medications, physician services, and preventive and therapeutic interventions. Coverage of obesity treatment under EPSDT is determined by whether a specific therapy is deemed medically necessary for the individual child. States may not arbitrarily exclude medically necessary treatments under EPSDT; however, they may implement utilization controls, including prior authorization requirements, clinical eligibility criteria (e.g., BMI thresholds and comorbidity assessment), and formulary management, provided these mechanisms do not effectively deny access to necessary care. When a clinician adequately documents that an obesity medication is necessary to treat or prevent significant health complications, EPSDT can serve as a basis to support coverage, even in states that otherwise restrict access to obesity pharmacotherapy [14,16]. It is important to note that the Children's Health Insurance Program (CHIP) does not include an equivalent to the EPSDT benefit, although such a framework may be warranted, particularly given the common scenario in which children transition between CHIP and Medicaid coverage. Persistent racial and ethnic disparities in access to obesity treatment, with minority and low-income underserved youth less likely to receive specialized care, further underscore the need to increase awareness and utilization of EPSDT to promote equitable access to treatment. Approximately half of U.S. children, and a disproportionate share of those with obesity, are insured through Medicaid or CHIP. Current evidence-based standards of care for pediatric obesity include intensive health behavior and lifestyle treatment, pharmacotherapy, and, when indicated, metabolic and bariatric surgery. EPSDT represents a critical mechanism to help bridge coverage gaps for these interventions, and clinicians must be prepared to leverage this benefit to ensure that patients receive appropriate, comprehensive care [28]. State-level examples of EPSDT in action Implementation of EPSDT for obesity pharmacotherapy is taking place across the country, but not uniformly. In this section and in Table 1, we provide examples from three states, Colorado, California, and Maine to illustrate the range of experiences: from early adoption and success stories to evolving challenges (Table 1, Table 2). Table 1State-level approaches to EPSDT implementation for pediatric obesity pharmacotherapy.Table 1StateStandard Medicaid Coverage for Obesity MedicationsEPSDT Implementation Year & General ProcessKey FeaturesColoradoExcluded (blanket exclusion for “weight-loss drugs” under Health First Colorado)Active since 2022. Direct EPSDT submission without requirement for initial denial. Requests reviewed by pharmacy benefit manager (PBM) pharmacist.-Eligibility criteria: Aligned with FDA labeling and 2023 AAP Clinical Practice Guideline; no additional restrictions-Time to decision: ∼48 h-Approval discretion: Reviewing pharmacist (from CO Medicaid's pharmacy benefit manager) determines approval and duration, typically a minimum of 12 months. Importantly, each dosage of medication does not require a separate authorization-Renewals: Allowed through age 21 with brief outcome updates (BMI, cardiometabolic, mental health, quality of life)-Comprehensive documentation: Letter of medical necessity explicitly requesting EPSDT review; includes BMI, comorbidities, prior therapies, engagement in intensive lifestyle treatment, rationale against lower-cost alternatives, and supporting literature-Operational infrastructure: Standardized EHR workflows, templated letters, and tracking via prior authorization tools-Team-based model: Critical players: nursing, medical assistants, medication access technician, ambulatory pharmacists, and government affairs-Access impact: ∼20 requests/week (∼10% of clinic population), enabling measurable expansion of evidence-based care-Policy innovation: Global Prior Authorization pathway for highly complex adults 21yo+ (≥8 medications + lifelong disability)-Forward planning: Structured transition strategies for patients aging out of EPSDT (e.g., alternate indications, manufacturer access, therapy changes)CaliforniaPreviously included (2019–2025) for select obesity medications (including GLP-1 RAs); coverage eliminated effective January 1, 2026 (budget-driven policy change)EPSDT pathway established 2026 after advocacy. Now case-by-case EPSDT prior authorization required for all pediatric obesity pharmacotherapy.-Policy shift: Transition from routine coverage to EPSDT-only access represents major access disruption-Eligibility criteria: Must meet FDA indication; BMI ≥30 kg/m2 required; no off-label approvals to date-Time to decision: ∼48–72 h via Medi-Cal PA portal-Documentation requirements: Robust medical necessity justification including BMI, comorbidities, prior therapies, lifestyle treatment engagement, rationale against alternatives, and supporting literature-Workflow burden: Requires proactive or rapid EPSDT submissions to prevent treatment interruption after denial-High-risk populations: Youth aging out at 21 (especially 21–25) face loss of access due to lack of adult coverage-System variability: Outcomes dependent on reviewer discretion; risk of inconsistent approvals-Policy lesson: Demonstrates volatility of coverage and reliance on EPSDT as a safety net rather than a comprehensive solution-Ongoing response: Active clinician education, advocacy, and research on impact of coverage lossMaineExcluded (no routine Medicaid coverage for obesity medications)Active since 2024. Requires initial PA denial, followed by EPSDT appeal.-Eligibility criteria: Youth 12–20 years with obesity and documented participation in structured lifestyle intervention-Clinical prioritization: Higher likelihood of approval in severe/complicated obesity (e.g., Class II with comorbidities)-Time to decision: ∼1–2 weeks-Approval standard: EPSDT mandate emphasized—requests approved if medically necessary and no contraindications-Documentation requirements: Explicit EPSDT-request including obesity trajectory, comorbidities, functional impact, prior treatments, and rationale for pharmacotherapy; references national guidelines (e.g., AAP 2023)-Implementation model: Standardized request templates across pediatric obesity centers-Early outcomes: >100 adolescents approved since 2024, demonstrating feasibility in a smaller state-Policy evolution: Ongoing evaluation of outcomes and budget impact; consideration of formalizing coverage without EPSDT requirement State-level approaches to EPSDT implementation for pediatric obesity pharmacotherapy. -Eligibility criteria: Aligned with FDA labeling and 2023 AAP Clinical Practice Guideline; no additional restrictions Eligibility criteria: Aligned with FDA labeling and 2023 AAP Clinical Practice Guideline; no additional restrictions -Time to decision: ∼48 h Time to decision: ∼48 h -Approval discretion: Reviewing pharmacist (from CO Medicaid's pharmacy benefit manager) determines approval and duration, typically a minimum of 12 months. Importantly, each dosage of medication does not require a separate authorization Approval discretion: Reviewing pharmacist (from CO Medicaid's pharmacy benefit manager) determines approval and duration, typically a minimum of 12 months. Importantly, each dosage of medication does not require a separate authorization -Renewals: Allowed through age 21 with brief outcome updates (BMI, cardiometabolic, mental health, quality of life) Renewals: Allowed through age 21 with brief outcome updates (BMI, cardiometabolic, mental health, quality of life) -Comprehensive documentation: Letter of medical necessity explicitly requesting EPSDT review; includes BMI, comorbidities, prior therapies, engagement in intensive lifestyle treatment, rationale against lower-cost alternatives, and supporting literature Comprehensive documentation: Letter of medical necessity explicitly requesting EPSDT review; includes BMI, comorbidities, prior therapies, engagement in intensive lifestyle treatment, rationale against lower-cost alternatives, and supporting literature -Operational infrastructure: Standardized EHR workflows, templated letters, and tracking via prior authorization tools Operational infrastructure: Standardized EHR workflows, templated letters, and tracking via prior authorization tools -Team-based model: Critical players: nursing, medical assistants, medication access technician, ambulatory pharmacists, and government affairs Team-based model: Critical players: nursing, medical assistants, medication access technician, ambulatory pharmacists, and government affairs -Access impact: ∼20 requests/week (∼10% of clinic population), enabling measurable expansion of evidence-based care Access impact: ∼20 requests/week (∼10% of clinic population), enabling measurable expansion of evidence-based care -Policy innovation: Global Prior Authorization pathway for highly complex adults 21yo+ (≥8 medications + lifelong disability) Policy innovation: Global Prior Authorization pathway for highly complex adults 21yo+ (≥8 medications + lifelong disability) -Forward planning: Structured transition strategies for patients aging out of EPSDT (e.g., alternate indications, manufacturer access, therapy changes) Forward planning: Structured transition strategies for patients aging out of EPSDT (e.g., alternate indications, manufacturer access, therapy changes) -Policy shift: Transition from routine coverage to EPSDT-only access represents major access disruption Policy shift: Transition from routine coverage to EPSDT-only access represents major access disruption -Eligibility criteria: Must meet FDA indication; BMI ≥30 kg/m2 required; no off-label approvals to date Eligibility criteria: Must meet FDA indication; BMI ≥30 kg/m2 required; no off-label approvals to date -Time to decision: ∼48–72 h via Medi-Cal PA portal Time to decision: ∼48–72 h via Medi-Cal PA portal -Documentation requirements: Robust medical necessity justification including BMI, comorbidities, prior therapies, lifestyle treatment engagement, rationale against alternatives, and supporting literature Documentation requirements: Robust medical necessity justification including BMI, comorbidities, prior therapies, lifestyle treatment engagement, rationale against alternatives, and supporting literature -Workflow burden: Requires proactive or rapid EPSDT submissions to prevent treatment interruption after denial Workflow burden: Requires proactive or rapid EPSDT submissions to prevent treatment interruption after denial -High-risk populations: Youth aging out at 21 (especially 21–25) face loss of access due to lack of adult coverage High-risk populations: Youth aging out at 21 (especially 21–25) face loss of access due to lack of adult coverage -System variability: Outcomes dependent on reviewer discretion; risk of inconsistent approvals System variability: Outcomes dependent on reviewer discretion; risk of inconsistent approvals -Policy lesson: Demonstrates volatility of coverage and reliance on EPSDT as a safety net rather than a comprehensive solution Policy lesson: Demonstrates volatility of coverage and reliance on EPSDT as a safety net rather than a comprehensive solution -Ongoing response: Active clinician education, advocacy, and research on impact of coverage loss Ongoing response: Active clinician education, advocacy, and research on impact of coverage loss -Eligibility criteria: Youth 12–20 years with obesity and documented participation in structured lifestyle intervention Eligibility criteria: Youth 12–20 years with obesity and documented participation in structured lifestyle intervention -Clinical prioritization: Higher likelihood of approval in severe/complicated obesity (e.g., Class II with comorbidities) Clinical prioritization: Higher likelihood of approval in severe/complicated obesity (e.g., Class II with comorbidities) -Time to decision: ∼1–2 weeks Time to decision: ∼1–2 weeks -Approval standard: EPSDT mandate emphasized—requests approved if medically necessary and no contraindications Approval standard: EPSDT mandate emphasized—requests approved if medically necessary and no contraindications -Documentation requirements: Explicit EPSDT Documentation requirements: Explicit EPSDT -request including obesity trajectory, comorbidities, functional impact, prior treatments, and rationale for pharmacotherapy; references national guidelines (e.g., AAP 2023) request including obesity trajectory, comorbidities, functional impact, prior treatments, and rationale for pharmacotherapy; references national guidelines (e.g., AAP 2023) -Implementation model: Standardized request templates across pediatric obesity centers Implementation model: Standardized request templates across pediatric obesity centers -Early outcomes: >100 adolescents approved since 2024, demonstrating feasibility in a smaller state Early outcomes: >100 adolescents approved since 2024, demonstrating feasibility in a smaller state -Policy evolution: Ongoing evaluation of outcomes and budget impact; consideration of formalizing coverage without EPSDT requirement Policy evolution: Ongoing evaluation of outcomes and budget impact; consideration of formalizing coverage without EPSDT requirement Table 2Quick-reference guide to EPSDT workflow for obesity pharmacotherapy.Table 2QuestionAnswer (Key Points)Who?Identify a team: Prescribing clinician plus support (nurse, pharmacist, medication access technician, coordinator, and/or medical assistant) to help with paperwork. In small offices, clinician and a staff member lead.When?Submit the PA/EPSDT request as soon as you decide the patient needs the medication. If initial denial occurs, move to appeal immediately (typically within 30 days).What?Prepare a comprehensive packet: clinic notes, growth charts, lab results, specialist reports, and a Letter of Medical Necessity explicitly requesting review under EPSDT. Include the phrase that standard Medicaid doesn't cover this service and EPSDT is being invoked.How?File via the Medicaid/insurance portal or fax using the standard PA form with EPSDT documentation attached. Use any state-specific EPSDT request forms if available. After submission, if no response by the expected time, follow up. If denied, file a written appeal citing EPSDT immediately. Follow-up with pharmacies to ensure they are able to access the approval and dispense.Where?Consult your state's Medicaid provider manual or website for specific instructions on EPSDT requests. (Appendix C lists state-specific guidance links.) Often, there's a dedicated section on EPSDT special services or an EPSDT coordinator contact.Why?Justification: Standard Medicaid likely excludes obesity drugs for adults, but federal law via EPSDT overrides those exclusions for kids because these treatments are medically necessary and are standard of care to ameliorate a serious health condition (obesity and its complications). Our duty is to advocate for access to evidence-based care. Quick-reference guide to EPSDT workflow for obesity pharmacotherapy. Colorado (CO) Background/impetus In Colorado, awareness of EPSDT as a mechanism to access obesity pharmacotherapy emerged in 2022, initiated by a parent advocate for a medically-complex adolescent. At the time, Health First Colorado (Colorado Medicaid) had a blanket exclusion for medications prescribed for “weight loss”, necessitating alternative access pathways. Process overview Colorado established a streamlined EPSDT submission and review process that does not require an initial denial. Requests are reviewed by Colorado Medicaid's pharmacy benefit manager (a third-party administrator of drug benefits), with decisions typically rendered within 48 h. Within the state's tertiary pediatric obesity program, which serves approximately 7000 unique patients annually, EPSDT requests for obesity pharmacotherapy average 15 per week (∼10% of patients). Workflow integration into the electronic health record and the addition of a dedicated medication access technician have improved efficiency and tracking. Eligibility criteria Criteria generally align with U.S. FDA labeling and the 2023 American Academy of Pediatrics clinical practice guideline, without additional restrictive thresholds. Clinical discretion is emphasized, and initial approval duration is determined on a case-by-case basis, but is typically 12 months. Letter of medical necessity components Letters typically include: •Obesity severity Obesity severity •Prior treatment attempts Prior treatment attempts •Justification for specific medication selection Justification for specific medication selection •Expected clinical outcomes (e.g., BMI reduction, cardiometabolic improvement, mental health, quality of life) and risk for disease progression if not treated Expected clinical outcomes (e.g., BMI reduction, cardiometabolic improvement, mental health, quality of life) and risk for disease progression if not treated Additional considerations As patients approach the EPSDT age limit (21 years), transition planning is required to mitigate treatment interruption. Colorado has also pursued broader policy solutions, including legislative efforts to expand obesity treatment coverage beginning in 2027. California (CA) Background/impetus Medi-Cal (California Medicaid) previously provided relatively broad coverage of obesity pharmacotherapy for adolescents (2019–2025), including GLP-1 RAs. However, a budget-driven policy change effective January 1, 2026, eliminated routine coverage for obesity indications, shifting access entirely to EPSDT for individuals under 21. Process overview Under the current framework, all pediatric obesity medication requests for Medi-Cal recipients require prior authorization through EPSDT, typically following or concurrent with a denial of standard coverage. Given California's large Medicaid population, this shift affects thousands of adolescents who were previously receiving therapy, creating substantial administrative burden for clinicians and health systems. Eligibility criteria State guidance currently requires: •Alignment with FDA-approved indications Alignment with FDA-approved indications •Documentation of BMI ≥30 kg/m2 Documentation of BMI ≥30 kg/m2 •Demonstration of medical necessity Demonstration of medical necessity Letter of medical necessity components Required elements include: •Detailed clinical justification for pharmacotherapy Detailed clinical justification for pharmacotherapy •Documentation of prior treatment attempts Documentation of prior treatment attempts •Evidence of risk for disease progression or complications Evidence of risk for disease progression or complications •Rationale for continued therapy in patients previously treated Rationale for continued therapy in patients previously treated Key considerations California illustrates the volatility of coverage and the reliance on EPSDT as a reactive safety net. Variability in case-by-case determinations raises concern for inequitable access. Additionally, individuals aging out of EPSDT at age 21 face abrupt loss of coverage, particularly impacting young adults aged 21–25, who no longer qualify for pediatric protections. Maine (ME) Background/impetus Following the 2023 pediatric obesity guidelines, MaineCare reassessed its exclusion of weight-loss medications. In early 2024, the state determined that obesity medications could be covered under EPSDT when medically necessary. Process overview Maine implemented a process in which a single, comprehensive EPSDT request is typically sufficient, without requiring multiple denials. Providers across the state developed standardized submission protocols to ensure consistency. Eligibility criteria Eligibility is based on: •Age <21 years Age <21 years •Diagnosis of obesity (typically severe) Diagnosis of obesity (typically severe) •Absence of contraindications Absence of contraindications Letter of medical necessity components Submissions generally include: •Clinical history and comorbidities (e.g., metabolic dysfunction-associated steatotic liver disease) Clinical history and comorbidities (e.g., metabolic dysfunction-associated steatotic liver disease) •Prior treatment attempts Prior treatment attempts •Rationale for medication use Rationale for medication use •Expected benefits and follow-up plan Expected benefits and follow-up plan Outcomes and lessons learned Maine's implementation has demonstrated steady uptake, with >100 adolescents approved for obesity pharmacotherapy via EPSDT since early 2024. Initial cases included adolescents with severe obesity, and approvals increased as clinician awareness grew. The state has begun tracking health outcomes, including weight and comorbidity improvement, to inform future policy decisions. Summary across states These examples demonstrate that while EPSDT provides a critical federal framework for access, implementation varies by state in terms of administrative processes, eligibility thresholds, and scale of use. Quantitatively, utilization ranges from targeted programmatic use (Colorado: ∼60 requests/month) to rapid policy-driven expansion (Maine: >100 approvals in ∼2 years) to large-scale reactive reliance following coverage withdrawal (California: thousands affected). Across all settings, successful implementation depends on clinician awareness, standardized and clear medical necessity documentation, and efficient workflows. Alternative state-level pathways to coverage Missouri Background In 2022, pediatric obesity clinicians providing tertiary care in Missouri began convening through the Missouri Council for Activity and Nutrition healthcare workgroup. These meetings focused on sharing best practices in obesity treatment, identifying support needs for primary care clinicians, and reviewing gaps in coverage for evidence-based interventions, including obesity pharmacotherapy. During this same period, clinicians raised concerns about the lack of Medicaid coverage for obesity medications with members of the Missouri Chapter of the American Academy of Pediatrics (AAP), who served on the Missouri Medicaid (MO HealthNet) Pharmacy Drug Prior Authorization Committee and had requested stakeholder input on the preferred drug list. This engagement led to an introductory meeting with the MO HealthNet Pharmacy Director and pharmacy leadership, facilitating ongoing dialogue between pediatric obesity specialists and Medicaid policymakers. Process overview Following initial engagement, regular collaborative meetings were established between tertiary care clinicians, MO HealthNet Pharmacy leadership, and medical directors from Missouri Medicaid managed care organizations. These meetings facilitated mutual education, updates on clinical evidence, and discussion of coverage barriers. From 2023 to 2024, MO HealthNet Pharmacy partnered with clinical stakeholders to conduct evidence-based reviews of obesity medications, develop utilization management criteria, and evaluate preferred drug list inclusion. A formal fiscal analysis was also completed to assess budget impact and support policy development for expanded coverage. After completion of internal approvals, Missouri Medicaid announced coverage of obesity pharmacotherapy for both adults and adolescents effective January 2025, initially limited to GLP-1 RAs. The rollout was accompanied by provider bulletins and dissemination through state professional organizations, along with educational materials (webinars and electronic resources) developed by MO HealthNet Pharmacy emphasizing the importance of concurrent intensive behavioral therapy and medical nutrition therapy. Since implementation, MO HealthNet Pharmacy, Medicaid managed care organizations, and tertiary pediatric obesity clinicians have continued regular meetings to monitor utilization, assess budget impact, and support ongoing provider education. In early 2026, driven by budget constraints, coverage policy was revised such that new prescriptions for GLP-1 RAs were restricted primarily to individuals with type 2 diabetes, with obesity indications considered only through case-by-case exceptions. A practical overview to securing EPSDT coverage Translating EPSDT for pediatric obesity from a legal mandate into routine clinical practice requires relationship building and clear workflows. In this section, we provide step-by-step guidance (Table 3 and Appendix A) that clinicians and care teams can follow when seeking Medicaid approval for obesity medications under EPSDT. This workflow can be adapted to practices of any size, from a solo provider with limited staff to a large multidisciplinary clinic. The keys are to identify and partner with key stakeholders, assign tasks, prepare documentation carefully, and be persistent through the insurance review process. Each step is outlined below, followed by a “quick reference” summary in Table 3 for handy reference in clinic. Table 3Documentation checklist for EPSDT medication requests.Table 3Documentation ItemDescription/TipsComprehensive Clinic NoteMost recent note detailing obesity history, prior interventions, and comprehensive review of systems. This provides context and shows the clinician's thorough assessment.Growth ChartWeight-for-age and BMI-for-age curves, or a series of BMI percentile data points over time. Illustrates the trajectory and persistence of obesity despite interventions.Problem List & ComorbiditiesUp-to-date list of diagnoses (e.g., obesity (severity); prediabetes; obstructive sleep apnea; etc.). Highlights the medical conditions that treatment will address.Laboratory/Diagnostic ResultsRelevant labs (e.g., fasting glucose, A1c, lipid panel, liver tests, blood pressure). Supports the presence of comorbidities like metabolic syndrome or prediabetes.Specialist ReportsConsult notes (endocrinology, cardiology, psychology, etc.) or results of studies (sleep study results, liver ultrasound, etc.) demonstrating complications of obesity.Lifestyle Therapy DocumentationProof of prior lifestyle therapy: dietitian notes, exercise program letters, participation in an obesity management clinic, etc. Validates that standard care (medications as an adjunct to lifestyle) are in place.Letter of Medical Necessity (Physician)Formal letter summarizing the case and explicitly stating the request under EPSDT. Should reference guidelines, medical necessity, and why this therapy is needed now.EPSDT/PA Request FormAny required state Medicaid forms for prior authorization or EPSDT exceptions. Fill these out meticulously. If no special form, use general PA form and write “EPSDT” in big letters at top.FDA Approval Evidence (if novel med)(Optional) FDA approval letter or label indications for the medication in pediatrics, if recently approved. Alternatively, pivotal trial reference (e.g., printout of NEJM study). Shows evidence base.State Medicaid Policy Excerpt(Optional) A copy of the state's formulary page showing the medication is excluded for adults. Paradoxically, including this can help, as you then argue EPSDT is the reason to override it.EPSDT Statute/Guidance Excerpt(Optional) A copy of the EPSDT rule text or state manual that says, “cover to ameliorate … even if not in state plan.” This can be attached as a gentle reminder of their obligation. Documentation checklist for EPSDT medication requests. First, clinicians should determine whether their state Medicaid program covers obesity medications (for the indication of obesity and/or obesity-related complications) and reviews any relevant pharmacy policies. Second, determine whether an EPSDT pathway exists for these medications; if unclear, direct engagement with Medicaid medical and pharmacy leadership and collaboration with regional obesity programs can help establish or clarify these processes. Third, identify eligible patients early, typically youth with obesity (BMI ≥95th percentile) who have not responded to lifestyle therapy, and document prior interventions and comorbidities. Fourth, assign clear team roles for clinical evaluation, documentation, submission, and patient support, adapting responsibilities to practice size and resources. This may mimic existing processes for various other medications requiring prior authorization. Fifth, prepare a documentation package, which may include a detailed clinical narrative, growth charts, prior treatment history, comorbidities, and a letter of medical necessity (Appendix B) that explicitly invokes EPSDT statutory language. Sixth, submit the prior authorization or EPSDT request promptly and track all submissions. Seventh, anticipate denials and pursue timely appeals that clearly explain why EPSDT requirements supersede standard coverage exclusions, supplementing with additional evidence as needed. Eighth, track outcomes systematically to refine workflows, identify barriers, and improve success rates over time. Finally, ongoing advocacy and collaboration with Medicaid stakeholders, institutional government affairs experts, and professional networks can help standardize processes and expand access. With experience, use of templates, and iterative improvement, this workflow becomes more efficient and increases the likelihood of approval, supporting equitable access to evidence-based obesity treatment in pediatrics (Table 3 and Appendix A). Challenges and limitations Implementing EPSDT-based coverage for obesity pharmacotherapy is not without challenges. While EPSDT offers a powerful legal lever, several barriers and limitations must be acknowledged. Lack of awareness and understanding Many clinicians, especially those not specializing in obesity or not familiar with Medicaid nuances, simply do not know about EPSDT or how to leverage it. This knowledge gap can result in eligible patients never being considered for medications or coverage. Likewise, families may be unaware of their rights under EPSDT and may not push back after an initial denial. Education is needed at all levels - providers, patients, Medicaid staff, about the EPSDT entitlement. Relatedly, an EPSDT process relevant to pediatric obesity treatment may first need to be created. Administrative burden The paperwork and time required can be daunting. Preparing detailed documentation and navigating the appeals process requires dedicated effort and expertise that can be burdensome. Unlike simply writing a prescription to a pharmacy, here the prescription/request is just the beginning of a potentially weeks-long administrative task. For some practices, especially those without support staff, this can be a real deterrent. Streamlining internal processes or sharing resources (like template letters, Appendix B) can help mitigate this, but it remains true that securing coverage under EPSDT demands more follow-up than a standard prescription. Variable interpretation of “medically necessary” States and even individual reviewers can differ in their threshold for what constitutes necessity. For instance, one Medicaid reviewer might agree that a 14-year-old with BMI in the 99th percentile and mild hypertension “needs” an obesity medication, while another might insist that only “life-threatening” conditions justify drug therapy. Some states may implicitly, or even explicitly, require the presence of comorbidities for approval, even though EPSDT's standard is broadly “correct or ameliorate” any condition (which should include obesity itself). This variability can lead to inconsistent outcomes. Robust national guidelines and accumulated successes will hopefully create a more uniform standard over time, but currently clinicians might get different decisions in different states, or even within the same state, until a precedent is established. Delays in care The appeals process can be slow. During the weeks or months it takes to secure approval, the patient is not yet receiving the treatment. In conditions like severe obesity, delays can mean further weight gain or continued health deterioration. There is also the risk of patient/family disengagement; some might give up if it takes too long. Families may choose to utilize unregulated compounded medications. Clear communication with families to set expectations and maintain engagement is crucial. Transition to adulthood A fundamental limitation of EPSDT is that it ends at age 21. For a 20-year-old who starts pharmacotherapy via EPSDT, turning 21 can abruptly cut off coverage, even if they still medically benefit from treatment. Similarly, EPSDT does not apply to 21–25-year-olds, a subgroup that many pediatric clinical programs treat (e.g. those with complex medical, neurodevelopmental, and psychosocial needs). This cliff effect is of great concern, as it may lead to weight regain and escalation of obesity and its complications, just as the individual enters adulthood. Discontinuing medication coverage would not be an accepted ethical practice for any other chronic disease. Some states or programs are exploring stop-gap measures (like extension of benefits or special young adult programs), but this remains a problematic limitation. Another important transition that can occur is if a young person transition to a different insurance at any time that does not have coverage during this process regardless of their age. Lifetime caps or funding limits A few states have historically attempted to impose lifetime benefit caps even on EPSDT services (e.g., a dollar limit on services per child, or limits on how many months a service can be provided). These are generally not permissible if the service is medically necessary, but creative administrative hurdles sometimes function as de facto caps. For example, a state might approve a medication only for 6 months and then require re-approval with evidence of effectiveness. If the patient does not meet an arbitrarily high bar of success, they might not receive medication renewal, effectively capping their treatment even though obesity is chronic and relapsing. Advocates argue that such practices violate the spirit of EPSDT. Bias and stigma in decision-making Bias against obesity can slip into the review process, consciously or subconsciously. A reviewer or committee might undervalue obesity treatment, perceiving it as lifestyle or cosmetic rather than medical, which can influence their decision to approve coverage. This contrasts with how they might consider a medication for, say, asthma, depression, or epilepsy. Combating this bias requires persistent framing of obesity as a disease with serious health consequences and drawing parallels to other chronic conditions. It may also involve advocacy and training at the Medicaid agency level to ensure decision-makers are approaching these requests without prejudice. Cost The cost of GLP-1 RAs and co-agonists in particular can pose an objective financial risk to insurance companies including state Medicaid plans. This has been exacerbated by the budget cuts imposed by House Reconciliation Bill 1 (July 2025). The result has been continued exclusion in states that never covered obesity medications and rescinding or restriction of access (for Medicaid and commercial plans) in several states, as exemplified in California above [27]. While upfront costs are still significant, having a long-term view of potential cost savings is essential from a public health perspective. Initiation of medications in childhood could help to prevent numerous obesity-related complications from ever occurring in adulthood. Limited economic analysis data in pediatrics show that phentermine plus topiramate is cost-effective and that semaglutide (Wegovy) showed the greatest improvement in quality and quantity of life (quality-adjusted life years) when started in adolescence, but requires cost reduction strategies [29,30]. Evolving market forces including competition with a strong pipeline for new medications are expected to drive costs down over time. Additional research focused on potential cost savings over the life course, particularly beginning in childhood, is critically needed. No single national policy Because Medicaid is state run (within federal guidelines), there is no central entity enforcing EPSDT uniformly for obesity treatment. There are potential benefits to this as individual states know their local landscape best and can respond and innovate effectively through local policies (Appendix C). However, the current patchwork means a child's access to care can depend on where they live—an inequity that is contrary to the intent of EPSDT. This challenge points to the need for coordinated intra- and interstate sharing and advocacy. Considering these challenges, what can clinicians and health teams do? The first step is to invest in learning and systematizing EPSDT processes. That means training staff, developing templates, and allotting time for these tasks as part of clinical care (considering it akin to prior authorization work that is unfortunately now part of many areas of medicine). Another step is to share knowledge: join a community of providers engaged in this work. Sometimes a quick email to a colleague in another state or a post on a professional forum can yield answers that save hours of frustration. Finally, clinicians should feel empowered to advocate beyond individual cases. This could involve presenting data from your clinic to state Medicaid advisory boards, participating in AAP chapter efforts to improve obesity care coverage, or even publishing case studies or commentaries on your EPSDT experiences. The more this issue is highlighted, the more likely systemic improvements will occur. EPSDT as a part of a broader policy landscape EPSDT is one powerful tool that should be considered in parallel with multi-pronged advocacy and policy initiatives designed to improve access to evidence-based care for youth with obesity. At the federal level these initiatives include negotiated payments across the US medication supply chain (i.e. pharmaceutical company/manufacturer, wholesaler, pharmacy benefit manager, pharmacy, insurance company). Recent federal initiatives including direct-to-consumer digital platforms offering lower out of pocket costs have been necessary but are insufficient to ensure equitable access to evidence-based obesity medication as they primarily target individuals who are able to pay for medications entirely out of pocket. The Center for Medicare and Medicaid Services Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) 2026–2027 initiative is an opt-in model whereby states may benefit from lower negotiated prices for GLP-1 medicines. However, aforementioned Medicaid budget cuts have limited state funds to match any new coverage resulting in hesitancy for state participation. At the state level (Appendix C), potential levers include expansion of state Medicaid pharmacy benefits and legislation focused on affordability reviews, pharmacy benefit manager regulation, consumer cost sharing, price gouging protections, reference rates, and importation. The National Academy for State Policy offers helpful state trackers to follow progress in each of these areas longitudinally [31]. The choice for which policies to prioritize and pursue will be state-specific and are decided through collaborative decision making among content experts and state Medicaid leadership (medical, pharmacy, utilization management). Pediatric clinicians desiring to meet with state Medicaid partners can utilize AAP and other advocacy resources and should seek permission to engage in discussions from their institution's/health system's government relations department; these departments can often be valuable allies to build collaborations. Discussion The emergence of highly effective obesity medications for youth has the potential to revolutionize pediatric obesity care, but only if patients can obtain these therapies on an ongoing basis. Safety and efficacy studies of the use of obesity medications in preadolescents are ongoing and results are promising. EPSDT remains the cornerstone of equitable pediatric healthcare coverage and is more relevant than ever in this context. This policy review and guide illustrate how clinicians can transform a legal benefit into tangible patient care, but it also raises important questions and areas for further discussion and research. First, the act of prescribing is now intimately tied to advocacy. For Medicaid-insured youth, writing a prescription for an obesity medication is often just the first step in a process that often includes a coverage appeal. Pediatric providers must expand their concept of their role to include being an advocate/navigator in the coverage realm. This is similar to how many pediatric oncologists or rare disease specialists have long had to operate (securing approval for expensive or off-label treatments), and now obesity medicine providers find themselves in that space. Medical training historically has not taught us how to perform this administrative advocacy, but perhaps it should, given how critical it is for patient outcomes. Second, there is a need for systematic data collection on EPSDT utilization and outcomes in the realm of obesity pharmacotherapy. At present, much of what we know is based on anecdote and local experience. If academic centers and Medicaid programs would partner to track process and effectiveness outcomes, we could generate stronger evidence to inform and refine policy. For instance, if it's documented that 100 youth in a state started a medication via EPSDT and 80 of them had significant BMI improvement and improved health metrics after a year, that data could be used to justify making the coverage permanent and easier (so-called “coverage with evidence development”). Conversely, tracking issues (like frequent denials due to certain documentation gaps) could pinpoint where additional provider education or policy clarification is needed. Additionally, federal-level guidance could be beneficial. The Centers for Medicare & Medicaid Services (CMS) periodically releases informational bulletins or clarifications on EPSDT obligations. A bulletin highlighting obesity as a condition requiring comprehensive treatment under EPSDT (including medications) might encourage more uniform adoption. Professional organizations can lobby for such guidance or even develop model legislation for states. Another discussion point is how to manage the transition beyond EPSDT-covered age. Perhaps the success of pediatric coverage will put pressure on adult Medicaid coverage to change. If states observe that treating 19-year-old yields health improvements and associated cost savings, it may create impetus to continue that treatment past age 21 to preserve health and wellbeing. There may also be innovative care models during transition to adulthood, such as extending EPSDT-equivalent benefits to age 25 for chronic diseases that began in childhood. In the interim, providers should counsel older adolescents about the limitation and, when possible, help them plan for next steps. The role of multidisciplinary teams and primary care deserves mention. While specialized obesity clinics are spearheading most of these EPSDT efforts now, the reality is that most children with obesity are managed in primary care settings. How can we disseminate this knowledge and processes to general pediatricians and family physicians? These clinicians may not have pharmacists or lawyers or policy experts on hand, so solutions like toolkits, tele-consultation support, or regional centers of excellence that assist community providers with EPSDT filings could be helpful. In essence, scaling up EPSDT usage will require empowering front-line providers with the resources and confidence to navigate it. From a societal perspective, equity is at the heart of this issue. Medicaid covers a large proportion of minority and low-income children [32], who also bear a disproportionate burden of obesity, and its complications [20]. If we fail to implement EPSDT fully for obesity care, we risk widening disparities, as more affluent families can access these new treatments (through private insurance or self-pay) while Medicaid-enrolled youth cannot. On the other hand, if EPSDT is effectively used, it can be a great equalizer, ensuring that a child's insurance status doesn't dictate whether they can receive state-of-the-art care for obesity. Continued advocacy is needed to fight weight stigma and secure recognition that treating obesity in youth is as important as treating any other chronic condition. Finally, we should discuss the lessons learned from EPSDT coverage of obesity in context of other conditions. EPSDT has been used to cover services like autism therapies, private duty nursing, and organ transplants for children without similar coverage for adults [[14], [15], [16], [17]].Advocates for this coverage faced initial pushback and required persistence. Over time, many of those services became routinely covered (or at least expected) for children. We may foresee a similar trajectory for obesity medications: what starts as case-by-case EPSDT exceptions would ideally become an accepted part of Medicaid's pediatric benefits. The guide presented here might, in a decade's time, become obsolete if all state Medicaid programs will include these medications as covered for children with medical necessity. That is the goal, to make equitable obesity care seamless and not contingent on separate, time-consuming processes. Until then, we operate in the current transitional period where EPSDT is a vital workaround to ensure our patients don't get sicker while they wait for the system to catch up. Limitations This review has several limitations. First, it is based largely on policy analysis, clinical experience, and selected state examples rather than systematic, nationally representative data; as such, the processes and outcomes described may not generalize to all Medicaid programs. Second, the rapidly evolving policy landscape, particularly recent changes in state coverage decisions and budget constraints, means that specific requirements, workflows, and access pathways may change over time, potentially limiting the durability of this guidance. Third, there is limited published evidence on real-world utilization, approval rates, clinical outcomes, and cost-effectiveness of obesity pharmacotherapy obtained through EPSDT, restricting the ability to quantify impact at scale. Fourth, variability in state interpretation of medical necessity and administrative processes introduces heterogeneity that cannot be fully captured in a single framework. Fifth, this guide emphasizes pharmacotherapy access and may not fully address parallel barriers to other evidence-based treatments. Finally, the recommendations may be more readily implemented in well-resourced or specialized settings, and feasibility in under-resourced or primary care environments may be more limited without additional infrastructure and support. Conclusion Clinicians can, and morally must, use EPSDT to secure Medicaid coverage for all evidence-based obesity pharmacotherapies for youth when medically necessary. Develop knowledge of pediatric obesity treatment coverage for your state's Medicaid plan; start the EPSDT process upon identification of an eligible patient; assemble the team you have; document medical necessity clearly; invoke the federal mandate that fills the holes in adult formularies; track your submissions; respond to denials; and share lessons learned. Although administrative complexity, state variability, age and lifetime caps, and persistent stigma make the journey challenging, EPSDT remains a lifeline: it exists precisely because standard Medicaid does not cover the interventions our patients need. Leveraging EPSDT is essential to reduce disparities, to shift cultural and payer mindsets about obesity as a chronic disease and to improve long-term health outcomes for vulnerable children. Clinical takeaways •Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit is a critical, underused mechanism to ensure equitable access to evidence-based obesity pharmacotherapy in youth with obesity. Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit is a critical, underused mechanism to ensure equitable access to evidence-based obesity pharmacotherapy in youth with obesity. •Successful implementation of EPSDT for pediatric obesity treatment requires structured clinical workflows and proactive documentation of medical necessity. Successful implementation of EPSDT for pediatric obesity treatment requires structured clinical workflows and proactive documentation of medical necessity. •Clinician engagement is central to translating policy into care, with EPSDT functioning as both a clinical tool and an advocacy framework. Clinician engagement is central to translating policy into care, with EPSDT functioning as both a clinical tool and an advocacy framework. Disclosures The authors have no financial relationships relevant to this article to disclose. Ethical adherence and ethical review This manuscript met exemption criteria for institutional review. Contributors' statements Jaime M, Moore, MD: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing; Valerie O'Hara, MD: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing; Cassie Totman: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing; Brooke Sweeney, MD: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing; Sarah Hampl MD: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing; Alaina P. Vidmar, MD: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review & Editing. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Consent for publication Not applicable. Availability of data and material Not applicable. Declaration of artificial intelligence (AI) and AI-assisted technologies During the preparation of this work the authors did not use AI. Source of funding This work was supported by grants 1) K23DK134801 NIH NIDDK (Vidmar), 2) K23HL163480 NIH NHLBI (Moore). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Brooke Sweeney has received research funding as a stie principal investigator from Rhythm Pharmaceuticals. Dr. Sweeney also has received consulting fees from Lilly Inc, Novo Nordisk, Rhythm Pharmaceuticals. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: K23DK134801 NIH NIDDK reports financial support was provided by National Institutes of Health. Jaime M. Moore reports financial support was provided by K23HL163480 NIH NHLBI. Within the past 24 months, Dr. Alaina P. Vidmar has received research funding as a site principal investigator from Eli Lilly and Company, Rhythm Pharmaceuticals, and Soleno Therapeutics. Dr. Vidmar has also served as an advisory board member for Soleno Therapeutics. In addition, Dr. Vidmar serves on the Board of Directors of the American Board of Obesity Medicine. All other authors declare no competing interests relevant to this manuscript. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements None. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.obpill.2026.100286. Contributor Information Jaime M. Moore, Email: JAIME.MOORE@CUANSCHUTZ.EDU. Valerie M. O'Hara, Email: voharado@gmail.com. Cassie Totman, Email: cassie.carpenter2@gmail.com. Brooke Sweeney, Email: brsweeney@cmh.edu. Sarah Hampl, Email: shampl@cmh.edu. Alaina P. Vidmar, Email: avidmar@chla.usc.edu. Supplementary data The following is the supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Not applicable.